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Vaccines Could Reduce Antimicrobial
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Outline
 Background on antimicrobial resistance (AMR)
 Main activities on animal health policies preventing and fighting
antimicrobial resistance (AMR) through Intergovernmental standards
and guidelines
 Focus on the OIE ad hoc Group on prioritisation of diseases for
which vaccines could reduce antimicrobial use in animals
 Conclusion
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Background
 +1 billion people by 2050
 Demand for animal protein,
increase by more than 50%

 Focus on developing
countries

Demand for food

Population growth
Globalisation
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 Unprecedented movement
of people and commodities

http://news.discovery.com/history/archaeology/antibiotic-genes-found-in-mummy-151020.htm

The One Health collaboration

Global leader for
food and
agriculture

Global leader for
animal health and
welfare standards

Global leader for
human health

Tripartite agreement
Collaborations
Joint priorities including Antimicrobial resistance (AMR)
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Outline
 Background
 OIE and activates on preventing and fighting antimicrobial
resistance (AMR)
 Focus on the OIE ad hoc Group on prioritisation of diseases for
which vaccines could reduce antimicrobial use in animals
 Conclusion
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OIE: an intergovernmental organisation founded

in 1924 : 180 Member Countries in 2016

1924

1945

Creation of the
Office
International des
Epizooties (OIE)
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2003

Creation of the
United Nations

World Organisation
for Animal Health
(OIE)

180 Member Countries in 2016

53
12
29
32
54
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17 Regional and Sub-regional Representations
OIE Headquarters
in Paris (France)
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5 Regional
Representations

8 Sub-Regional
Representations and Sub-Regional
Offices

OIE intergovernmental Standards
CODES
•
•

Terrestrial
Aquatic

MANUALS
•
•

Terrestrial
Aquatic

Codes and Manuals available on the OIE website
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Terrestrial Manual - Purpose
 Describes internationally agreed standard
laboratory methods for disease diagnosis
 Describes requirements for the production and
control of vaccines and other biological products

 Available in full and up to date on line in English
and Spanish at http://www.oie.int/en/internationalstandard-setting/terrestrial-manual/access-online/
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Terrestrial Manual – Part 3
General Guidelines
3.1 Laboratory methodologies for bacterial antimicrobial
susceptibility testing
3.2 Biotechnology in the diagnosis of infectious diseases
3.3 The application of biotechnology to the development of
veterinary vaccines
3.4 The role of official bodies in the international regulation of
veterinary biologicals
3.5 Managing biorisk: examples of aligning risk management
strategies with assessed biorisks
3.6 OIE Validation Guidelines
12

OIE activities on preventing and fighting AMR
 Initiatives to improve good governance of veterinary
services
 Global database on antimicrobials use in animals
worldwide
 Contributing to the availability of quality assured
antimicrobials and their prudent and responsible use

 List of antibiotics of critical importance for animal health
 Ad hoc Group on AMR and ad hoc Group on prioritization of
diseases for which vaccines could reduce AMR in animals
 2nd International Symposium on Alternatives to
Antibiotics for Animal Production (USDA with the support
of the OIE), 13-15 December 2016, Paris (France)
13

Outline
 Background
 OIE and activates on preventing and fighting antimicrobial
resistance (AMR)
 Focus on the OIE ad hoc Group on prioritisation of diseases for
which vaccines could reduce antimicrobial use in animals
 Conclusion
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Purpose of the ad hoc Group
 “Provide guidance on prioritisation of disease for which
the use of already available and new vaccines could
reduce antimicrobial use in animals, focusing the first
step on pigs, poultry and fish “

 Identify actions to improve utilisation of such vaccines
 To support the WHO Global Action Plan on AMR which
makes provision for such approach
15

Terms of Reference (ToR)
 Consider disease for which the availability and use of
appropriate vaccines could reduce antimicrobial use in
animals
 Rank bacterial disease in terrestrial (pig and poultry) and
aquatic (fish) animals by animal group, which cause the
highest use of antimicrobials in the animal concerned

 Refine the ranking by considering relevant factors
impacting vaccine development, effectiveness or
implementation of vaccination
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Methodology
 Development of a template and guiding criteria for the
ranking of diseases:
• For the purpose of stimulating research into new or
better adopted vaccines with the aim of reducing the
use of antibiotics
• The development of multivalent vaccines should
potentially cover a broad range of issues and
disciplines, including discovery of new aetiological
agents
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Methodology
Proposed chicken, swine and fish diseases where development or improvement of
vaccines would have a high impact on antibiotic use :
Key principles:
1. Identification of the most prevalent and important bacterial infections in chickens,
swine, and identification of fish species that are commonly farmed and associated with
high antibiotic use, and associated prevalent bacterial infections in those species.
2. Identification of common non-bacterial infections in chicken, swine and fish (e.g.
protozoal, viral) showing clinical signs that trigger empirical antibiotic treatment (e.g.
for diarrhoea) and which also result frequently in bacterial co-infection.
3. An assessment of antibiotic use in response to the syndromic indication or diagnosed
disease. This was categorised as high, medium or low in the context of considered
use compared with the total use of antibiotics in that animal species.
4. The availability of a vaccine(s), and if available, their effectiveness.
5. The potential for a new or improved vaccine to reduce the need for antibiotic treatment
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Tables: Infections for which new or improved vaccines
would significantly reduce the need for antibiotic use
(chicken, swine or fish)

19

Key syndrome

Commercial vaccine
exists

Primary pathogen(s)
(disease)

Major constraints to
use of vaccine /
vaccine development

Antibiotic use

Vaccine research
priority

Table 1: Infections for which new or improved vaccines would significantly
reduce the need for antibiotic use in chickens
Key syndrome

Primary pathogen(s)
(disease)
Escherichia coli
(Yolk sac infection, airsacculitis,
cellulitis)

Antibiotic
use

Commercial*
vaccine exists

High

Yes

Systemic
(Broilers)
Infectious Bursal Disease virus
(secondary bacterial infections)
Systemic
(Breeders,
Layers)

Major constraints to use of vaccine /
vaccine development




Omphalitis: secondary bacterial infection
– not a disease one can immunize
against
Strain coverage limited
Airsacculitis, cellulitis: vaccines available,
e.g. live aerosol vaccine. However,
Serotype coverage limited and field
efficay variable

Yes





Issues with vaccine application
Short window of opportunity to vaccinate
Maternal antibody interference

Escherichia coli
(airsacculitis, cellulitis, salpingitis
and peritonitis)

High

Yes



Strain coverage limited

High

Clostridium perfringens, type A
(necrotic enteritis)

High

Yes



Toxoid vaccine for layers providing only
short-lasting passive immunity
Research needed to achieve active
immunity.
Improved and/or more convenient (mass
vaccination) vaccine needed for broilers

High

Lack of cross-protection
Strains must be matched to infectious
agent
Current vaccines are not attenuated and
can produce low dose infection
Sub-unit
vaccines
have
not
been
successful

High

Issues with strain matching and strain
coverage
High mutation rate of virus

Medium


Coccidiosis
(secondary bacterial infections)

High

Yes






Infectious Bronchitis virus
(secondary bacterial infections)

Medium

Yes




*

High

Medium



Enteric
(Broilers,
Breeders, and
Layers)

Vaccine
research
priority

does not cover autogenous vaccines

Medium

Report of the meeting of the OIE ad hoc Group on
Prioritisation of Diseases for which Vaccines could
Reduce Antimicrobial Use in Animals
Poultry diseases
 Escherichia coli (Yolk sac infection, airsacculitis, cellulitis) (H)
 Clostridium perfringens, type A (necrotic enteritis) (H)
 Coccidiosis (secondary bacterial infections) (H)
 Infectious bronchitis virus (secondary bacterial infections) (H)
 Infectious bursal disease virus (secondary bacterial infections) (M)
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Table 2: Infections for which new or improved vaccines would significantly
reduce the need for antibiotic use in swine
Key syndrome
Systemic
(respiratory)

Primary pathogen(s)
(disease)

Commercial*
vaccine exists

High

Yes





Strain coverage too narrow
Lack of cross-protection
Poor immunogenicity due to being a capsule
based vaccine

Medium

Yes



Serotype specific with variable crossprotection
Maternal antibody interference

Pasteurella multocida (for
pneumonic disease)

High

No



No vaccine with approved label claim for
pneumonia
(There is a vaccine for atrophic rhinitis)

High

Mycoplasma hyopneumoniae

High

Yes





Does not completely prevent lung lesions
Animals continue to shed pathogen
Diagnostics not always accurately done

Low

Actinobacillus
pleuropneumoniae

High

Yes





Limited coverage
Good immunity only if serotype specific
Sub-unit vaccine which affords crossprotection

High

Porcine Reproductive and
Respiratory Syndrome virus
(secondary bacterial infections)

High

Yes






Strain coverage limited
High virus mutation rate
Modest cross-protection
Vaccine evasion

High

Swine Influenza Virus
(secondary bacterial infections)

High

Yes




Strain matching
Vaccine-associated enhanced respiratory
disease (VAERD)
Lack of cross-protection
Efficacy in piglets limited

High

Maternal vaccine provides effective
lactogenic immunity
Coverage of enterotoxigenic E. coli may
occasionally need to be updated

Low

Streptococcus suis

Haemophilus parasuis

Major constraints to use of vaccine /
vaccine development


Respiratory



Enteric – neonatal

Enteric
(weaners/finishers)

Vaccine
research
priority

Antibiotic use



High

Medium

High for the
syndrome,
Low for E. coli

Yes

Escherichia coli

High

Yes




Maternal antibody interference
Short window for induction of immunity

High

Lawsonia intracellularis

High

Yes



Other pathogens in the syndrome
(Brachyspira) not included
Antibiotic-free window for vaccination
required (live attenuated oral vaccine)

Low
(see also
Brachyspira)

Escherichia coli




Brachyspira spp
B. hyodysenteriae,
B. pilosicoli
Rotaviruses (secondary
bacterial infections)

Medium-high

High

No

Yes



High



Low current research investment as changes
in husbandry largely eliminated the disease
Technical barriers to vaccine development



Reasons limiting wider adoption unknown

High

Report of the meeting (contd)
Swine diseases

 Streptococcus suis (H)
 Pasteurella multocida (for pneumonic disease) (H)
 Actinobacillus pleuropneumoniae (H)
 Porcine reproductive and respiratory syndrome virus (H)
 Swine influenza virus (H)
 E. coli (H)
 Brachyspira spp. including B. hyodysenteriae and B. pilosicoli (H)
 Rotaviruses (secondary bacterial infections) (H)
 Haemophilus parasuis (M)
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Table 3: Infections for which new or improved vaccines would significantly
reduce the need for antibiotic use in fish
Key syndrome
or disease

Primary pathogen(s)

Antibiotic
use

Commercial*
vaccine exists

Major constraints to use of vaccine /
vaccine development

Vaccine research
priority

Freshwater cyprinids
Systemic
bacterioses

Aeromonas hydrophila and
other species

High

No



Disease is caused by a wide range of
serotypes

High

Dermal
bacterioses /
red spot
disease

Pseudomonas spp.

High

No



Disease is caused by a range of
species and wide range of strains and
serotypes

High

Columnaris

Flavobacterium columnare

Medium

Yes



Limited uptake by some countries for
unknown reasons

Low

Aeromonas hydrophila and
other species

Medium

No



Disease is caused by a range of
species and wide range of strains and
serotypes

Streptococcus inae,
S. agalactiae

Medium

Yes



Industry awareness of need is low (first
vaccine only became recently
available)

Aeromonas salmonicida,
Yersinia rukerii,
Flavobacterium
psychrophilum,
Vibrio anguillarum

Medium

Yes
(multivalent,
injectable)



cost of vaccine is high relative to
harvest value

Piscirickettsia salmonis

Medium

Yes



Multivalent vaccine which provides low
protection for P. salmonis compared to
other pathogens included in the
vaccine.

Vibrio spp.,
Photobacterium spp.

Medium

Yes



Disease is caused by a wide range of
serotypes
Industry awareness is low in some
countries

High

Disease is caused by a wide range of
serotypes
Industry awareness is low in some
countries

High

Vaccines are not available for African
catfish (an important farmed species)
Vaccines have very recently become
available for Tra catfish and yet to be
adopted by the industry

High
(for African catfish)

Disease is caused by a wide range of
serotypes

High

Freshwater cichlids

Systemic/dermal
bacterioses

Medium (not low
because of
projected increase
in production)
Medium

Freshwater salmonids
Systemic
bacterioses

Low

Marine salmonids
Salmon
Rickettsia
Syndrome

Unknown because
the recent
introduction of an
oral monovalent
vaccine booster
may improve the
level of protection

Other marine fish

Systemic /
dermal
bacterioses


Streptococcus spp.

Medium

Yes




Catfish
Systemic

Systemic

Edwardsiella ictaluri,
E. tarda

Aeromonas hydrophila and
other species

Medium

Medium

Yes
(for Channel
catfish)



No





Report of the meeting (contd)
Fish diseases

 Aeromonas hydrophila and other species (Freshwater cyprinids) (H)
 Pseudomonas spp. (Freshwater cyprinids) (H)
 Vibrio spp., (Marine fish) (H)
 Photobacterium spp. (Marine fish) (H)
 Streptococcus spp. (Marine fish) (H)
 Edwardsiella ictaluri, E. tarda (Catfish) (H)
 A. hydrophila and other species (Catfish) (H)
 Streptococcus inae, and S. agalactiae (Freshwater cichlids) (M)
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Outcome
 In vaccine research could have a significant impact,
particularly if it addressed the following four priority gaps:
• Maternal antibody interference
• Cross-protection or inclusion of relevant strains in vaccine
formulations
• Occurrence of immunological interference in multivalent
vaccines
• Innovative delivery systems to enable mass-vaccination
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CONCLUSION
 A global vaccine research network should be created to pull
resources and expertise to address gaps for each of the priority
diseases listed in Table 1-3. (Annex 5 of the Scientific Commission
Report)
http://www.oie.int/fileadmin/Home/eng/Internationa_Standard_Setting/docs/pdf/SCAD/
A_SCAD_Sept2015. pdf

 Call for encouragement for development for new technologies and
handle the major shift on how vaccine discovery research may
provide new opportunities for addressing the challenges
 Need to invest for new or improved vaccines in order to reduce
antibiotic use in the animals (as presented in details in the report
and tables).
 Public-Private partnership are key
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Information is available at the OIE website
ANTIMICROBIAL RESISTANCE (AMR)
http://www.oie.int/en/our-scientific-expertise/veterinaryproducts/antimicrobials/
• http://www.oie.int/en/for-the-media/amr/multimediaressources/
REPORT
• http://www.oie.int/fileadmin/Home/eng/Internationa_Stan
dard_Setting/docs/pdf/SCAD/A_SCAD_Sept2015.pdf
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ATTENTION !
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